The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324.
 
Sonja Loges
Research Funding - BerGenBio (Inst)
Travel, Accommodations, Expenses - BerGenBio
 
Isabel Ben Batalla
Research Funding - BerGenBio (Inst)
 
Michael Heuser
Research Funding - BerGenBio (Inst)
 
Nikolas Berenbrok
No Relationships to Disclose
 
Thomas Schroeder
No Relationships to Disclose
 
Stefanie Geyh
No Relationships to Disclose
 
David Micklem
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Patents, Royalties, Other Intellectual Property - BerGenBio
 
Jörg Chromik
Research Funding - BerGenBio (Inst)
 
Maxim Kebenko
No Relationships to Disclose
 
Walter M. Fiedler
No Relationships to Disclose
 
Murray Yule
Employment - BerGenBio
Leadership - BerGenBio
Honoraria - BerGenBio
Consulting or Advisory Role - BerGenBio
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst)
 
Bjorn T. Gjertsen
Research Funding - BerGenBio (Inst)